Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
| Image |  |
|---|---|
| Description | scientific article published on 01 January 2020 |
| Author/s |
author: Oliver P Gautschi Gebra Cuyun Carter Odd Terje Brustugun |
| Publication date | January 1, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |